Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-10 of 10 for your search:
Drug:
polifeprosan 20 with carmustine implant
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Evaluation Of Convection Enhanced Delivery Of IL13-PE38QQR (Interleukin-13 PE38QQR Immunotoxin) Compared To Gliadel® Wafer (Polifeprosan 20 With Carmustine Implant) In Glioblastoma Multiforme Patients At First Recurrence
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
NEOPHARM-IL13PEI-301
, UCLA-040305101, NEOPHARM-IL13PEI-301-R01, PRECISE, NCT00076986
2.
Phase II Study of Gliadel Wafers in Adults with Recurrent Supratentorial Low Grade Glioma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
DUMC-1706-02-9R5
, DUMC-1706-01-9R4, DUMC-000693-00-4, DUMC-1509-97-10, DUMC-1568-98-10R1, DUMC-1706-00-9R3, DUMC-97131, NCI-G98-1470, NCT00003467
3.
Phase II Study of Polifeprosan 20 with Carmustine Implant (Gliadel Wafers) in Patients With Supratentorial Brain Metastases Undergoing Surgical Resection
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NABTT-9802
, JHOC-NABTT-9802, NCT00003878
4.
Phase II Study of Polifeprosan 20 With Carmustine Implant (Gliadel Wafer®) and O6-Benzylguanine in Patients With Recurrent Glioblastoma Multiforme
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
DUMC-5515-06-1R2
, DUMC-5515-04-1R0, GP-DUMC-5515-06-1R2, NCT00362921
5.
Phase I Study of Gliadel Wafers (Carmustine) Plus Irinotecan in Patients with Recurrent Supratentorial High Grade Gliomas
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
DUMC-0901-02-5R4
, DUMC-0901-02-5R2, DUMC-000901-00-5R2, DUMC-000901-01-5R3, DUMC-0797-99-5RI, DUMC-796-98-5, DUMC-98065, UCLA-9812060, NCI-G98-1464, DUMC-0901-01-5R3, NCT00003463
6.
Phase I Study of Polifeprosan 20 with Carmustine Implant (Gliadel Wafers) in Children and Adolescents with Recurrent Supratentorial Glial Tumors (Summary Last Modified 11/1999)
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
Under 18
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
RP-RPR132596-150MA
, NCI-V98-1465
7.
Phase I Study of Concurrent Permanent Iodine I 125 Interstitial Seed Implants and Polifeprosan 20 With Carmustine Implant (Gliadel Wafers) in Patients With Recurrent or Refractory Malignant Glioma (Summary Last Modified 05/2001)
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UCMC-98724
, UCMC-55853, NCI-V99-1543, NCT00003876
8.
Phase I Study of Polifeprosan 20 with Carmustine Implants (Gliadel Wafers) plus Temozolomide in Patients with Recurrent Supratentorial High Grade Glioma (Summary Last Modified 03/2000)
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCLA-IRB-9812061
, NCI-G99-1600
9.
Phase I Study of Polifeprosan 20 With Carmustine Implants (Gliadel Wafers) and O6-Benzylguanine in Patients With Recurrent Malignant Glioma
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NABTT-9803
, JHOC-NABTT-9803, NCT00004892
10.
Phase I Study of Polifeprosan 20 With Carmustine Implant (Gliadel) and O(6)-Benzylguanine in Pediatric Patients With Recurrent Malignant Glioma
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
3 to 21
Sponsor:
NCI
Protocol IDs:
PBTC-009
, NCT00045721
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute